Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

342,868 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/05/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/05/2020.
Displaying: 86,103 trials in your specialties ()
View trials across your selected specialties

Inflammatory Response In Schizophrenia

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Schizophrenia
View Full Trial
INTERVENTION

Drug: Natalizumab, Other: Placebo: normal saline

Eligibility
  • Ages: 18 to 50 Years (Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
Locations

Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom

Brief Summary

Schizophrenia affects a significant proportion of the population and current levels of understanding of the illness is inadequate to treat it effectively. Converging lines of evidence suggest that neuroinflammation occurs in schizophrenia, and specifically over-activity of brain-resident immune cells called microglia. It is however unclear whether activated microglia play a primary role in schizophrenia, or whether this is a secondary phenomenon of no pathophysiological significance. The investigators therefore plan to test the effect of a monoclonal antibody (natalizumab) on psychotic symptoms in a cohort of first episode psychosis patients.

The Effect of Intra-Articular Injection of RegenoGel-OSP™ (Self-Plasma) and RegenoGel™ on Knee Pain in People Suffering From Osteoarthritis

  • Status
    Active, not recruiting
  • Phase
    Phase 4
  • Condition
    Osteoarthritis, Knee
View Full Trial
INTERVENTION

Device: RegenoGel-OSP, RegenoGel

Eligibility
  • Ages: 55 to 80 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Hadassah Medical Center, Jerusalem, Israel

Brief Summary

This study evaluates the efficacy of intra-articular administration of RegenoGel-OSP™ and RegenoGel™ to treat knee pain and effect on subject's activity and quality of life. During the study the subjects will receive two treatments at a 3-month interval. The study is double-blinded. The subjects will be randomized and sequentially assigned to RegenoGel-OSP™, RegenoGel or placebo treatment in the first treatment. In the second treatment after interval of three months all the subjects will necessarily receive one of the two active products. The follow-up period will continue for one year after first treatment.

Study of BTK Inhibitor BGB-3111 in Subjects With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Diffuse Large B Cell Lymphoma
View Full Trial
INTERVENTION

Drug: BGB-3111

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Peking University Cancer Hospital, Beijing, Beijing, China

Brief Summary

Screening (up to 28 days); daily treatment until disease progression, unacceptable toxicity or death, withdrawal of consent, lost to follow-up, or study termination from sponsor; treatment (up to 2 years), safety follow-up (30 days); survival follow-up until data cutoff for final analysis.

A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Osteosarcoma
View Full Trial
INTERVENTION

Drug: Avelumab, Other: Questionnaires

Eligibility
  • Ages: 12 to 49 Years (Child, Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Children's Hospital Los Angeles, Los Angeles, California, United States

Brief Summary

This clinical trial seeks to determine if avelumab will be effective in facilitating removal of all gross tumor in the event of a relapse of osteosarcoma in pediatric patients. Avelumab will be evaluated using dosing that has previously been determined in adult studies. Primary Objectives: - To estimate the response rate to 4 cycles of avelumab in patients with recurrent or progressive osteosarcoma. - To estimate the 16-week progression free survival of patients with recurrent or progressive osteosarcoma after treatment with avelumab. Secondary Objective: - To describe the toxicities associated with the administration of avelumab in patients with recurrent or progressive osteosarcoma. - To assess the quality of life of patients with recurrent or progressive osteosarcoma undergoing treatment with avelumab, and to explore relationships between clinical factors and patient-reported health-related quality of life (HRQOL) outcomes. Exploratory Objectives: - To explore factors associated with response in patients treated with avelumab after recurrent or progressive osteosarcoma (e.g. tumor PD-L1 expression). - To measure parameters of immune activation including subsets of peripheral blood mononuclear cells (PBMCs) and serum markers of immune activation. - To evaluate the role of T-cells in immune checkpoint blockade via measures of cell proliferation, co-inhibitory receptor expression on CD8 T cells, T cell repertoire, and epigenetic programming.

Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine

  • Status
    Active, not recruiting
  • Phase
    Phase 3
  • Condition
    Migraine
View Full Trial
INTERVENTION

Drug: TEV-48125, Drug: TEV-48125

Eligibility
  • Ages: 18 to 70 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Saitama Medical University Hospital, Iruma, Japan

Brief Summary

To evaluate the long-term safety and tolerability of subcutaneous (SC) administration of TEV-48125 (at 225 mg once monthly [except for a loading dose of 675 mg for CM patients] or at 675 mg every 3 months) for the preventive treatment of Chronic Migraine and Episodic Migraine patients

Indocyanine Green for Central Nervous System Tumors

  • Status
    Active, not recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Suspected Central Nervous System Tumors
View Full Trial
INTERVENTION

Drug: Indocyanine Green (ICG), Radiation: intraoperative near-infrared (NIR)

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Brief Summary

A specific aim is to determine if Indocyanine Green (ICG) administered pre-operatively, then imaged intraoperatively using our camera will aid in the identification of suspected central nervous system (CNS) tumors. A secondary aim is to understand if the use of ICG during surgery correlates to MR imaging findings including elevated Cho/Cr ratio, rCBV, Ktrans and contrast enhancement.

A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Chronic Lymphocytic Leukemia
View Full Trial
INTERVENTION

Drug: ABT-199

Eligibility
  • Ages: 18 to 99 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Ucsd /Id# 128535, La Jolla, California, United States

Brief Summary

This is an open-label, non-randomized, multicenter, Phase 2 study evaluating the efficacy and safety of ABT-199 in approximately 120 subjects with relapsed or refractory CLL after B-cell receptor signaling pathway inhibitors (BCR PI) treatment.

Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Tuberculosis, Multidrug-Resistant
View Full Trial
INTERVENTION

Drug: Levofloxacin, Drug: Optimized background regimen (OBR)

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Partners in Health, Lima, Peru

Brief Summary

Multi-drug-resistant tuberculosis (MDR-TB) affects nearly 600,000 persons each year around the world. This type of tuberculosis is very difficult to treat, and many patients die from it. Drugs of the fluoroquinolone class are very important for treating MDR-TB, but the best dose of one of the most effective fluoroquinolones, levofloxacin, is not known. This application proposes a study to determine the best dose of levofloxacin to use in treating MDR-TB. 120 patients will receive their usual treatment, plus levofloxacin at one of four doses. The study will be performed in Peru and in South Africa, where MDR-TB is common.

Breathe Anew for Lung Cancer Survivorship

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Lung Cancer
View Full Trial
INTERVENTION

Combination Product: Breathe Anew Survivorship Program

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada

Brief Summary

Survivorship programs have become an integral component of modern cancer care programs. In Canada, there has been tremendous success for survivorship programs for breast, prostate, and colorectal cancer, however lung cancer survivorship programs have not been widely developed. The complexity of the disease, high mortality, short survival times, high cost of surveillance, and patient habits have traditionally been barriers against the success of lung cancer survivorship programs. The investigator proposes a feasibility study to pilot a novel intervention titled Breathe Anew, which will aim to identify and overcome the barriers to the design and implementation of a lung cancer survivorship program. The investigator has assembled a multi-disciplinary team of experts and lung cancer survivors who will develop the Breathe Anew survivorship intervention. The intervention will be vetted using an integrated knowledge translation approach, which will involve members of the target population, primarily patients who previously underwent lung resection, to modify the intervention and ensure acceptability. After Breathe Anew has been designed, it will be tested in a pilot study of 50 patients to ensure its feasibility and determine its cost. The ultimate goal of this feasibility study is to lay the groundwork for a subsequent comparative trial to evaluate the impact of Breathe Anew on patient-important outcomes including health related quality and length of life and postoperative complications.

A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Allografts, Transplant Rejection, Kidney Transplantation, Rejecti...
View Full Trial
INTERVENTION

Drug: Belatacept, Drug: VIB4920

Eligibility
  • Ages: 18 to 70 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

University of California, San Francisco, San Francisco, California, United States

Brief Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of dual costimulation blockade with VIB4920 in combination of belatacept in adult male or female recipients of a renal allograft from a deceased, living unrelated or human leukocyte antigen (HLA) non-identical living related donor.